我的主要研究重點是流感疫潮的防備和應對。我開發了一些數學模型，用來評估不同的流感疫潮緩解和監控策略的潛在優勢和邏輯要求。具體議題包括以家庭 為基礎 的公共衞生干預措施，病毒流行前疫苗的分級分配，最大限度地減少抗藥性的多種藥物儲備方式，有組織的恢復期血漿治療計畫，及用血清學監測來即時估算嚴重程 度。除了流感疫潮的建模，我近期的項目包括有：（i）不同的策略進行香港宮頸癌篩查和HPV疫苗接種的成本效益分析（ii）傳染病流行病學的實地研究。 

我是香港衞生署衞生防護中心科學委員會成員。我同時也是美國哈佛大學公共衞生學院的傳染病動力學中心（CCDD）附屬教員。我負責協調每年CCDD傳染病建模的短期課程，其目的是為公共衞生專業人員提供傳染病建模的原理和應用的概述。我還是美國流行病學學報的副主編。 

於二零零三年在麻省理工學院，我在運籌學研究獲得哲學博士學位，一九九九年獲得化學工程學士學位。在加入香港大學之前，我曾任職於佐治亞理工大學工業及系統工程學學院的助理教授，還在洛斯阿拉莫斯國家實驗室的理論生物學和生物物理學小組進行過博士後的研究。 

1. Wu JT, Leung K, Bushman M, Kishore N, Niehus R, M de Salazar P, Cowling B J, Lipsitch M, Leung GM. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nature Medicine. 2020.
   Impact factor: 36.13; No. of citations: 285;
   Ranking: 2/297, Q1 in Biochemistry & Molecular Biology; 3/195, Q1 in Cell Biology; 1/138, Q1 in Medicine, Research & Experimental
2. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. Lancet. 2020; S0140-6736(20)30260-9.
   Impact factor: 60.392; No. of citations: 1016;
   Ranking: 2/165, Q1 in Medicine, General & Internal
3. Wang L, Wu JT. Characterizing the dynamics underlying global spread of epidemics. Nature Communications 2018, 9(1):218.
   Impact factor: 12.121; No. of citations: 66;
   Ranking: 6/71, Q1 in Multidisciplinary Sciences
4. Leung K, Lipsitch M, Yuen KY, Wu JT. Monitoring the fitness of antiviral-resistant influenza strains during an epidemic: a mathematical modelling study. The Lancet Infectious Diseases 2017, 17(3):339-347.
   Impact factor: 24.446; No. of citations: 6;
   Ranking: 1/93, Q1 in Infectious Diseases
5. Wu JT, Peak CM, Leung GM, Lipsitch M: Fractional dosing of yellow fever vaccine to extend supply: a modelling study. Lancet 2016, 388(10062):2904-2911.
   Impact factor: 60.392; No. of citations: 33;
   Ranking: 2/165, Q1 in Medicine, General & Internal
6. Wu JT, Jit M, Zheng Y, Leung K, Xing W, Yang J, Liao Q, Cowling BJ, Yang B, Lau EH et al: Routine Pediatric Enterovirus 71 Vaccination in China: a Cost-Effectiveness Analysis. PLoS medicine 2016, 13(3):e1001975.
   Impact factor: 10.5; No. of citations: 27;
   Ranking: 8/165, Q1 in Medicine, General & Internal
7. Wu JT, Ho A, Ma ES, Lee CK, Chu DK, Ho PL, Hung IF, Ho LM, Lin CK, Tsang T et al. Estimating Infection Attack Rates and Severity in Real Time during an Influenza Pandemic: Analysis of Serial Cross-Sectional Serologic Surveillance Data. PLoS medicine 2011, 8(10):e1001103.
   Impact factor: 10.5; No. of citations: 47;
   Ranking: 8/165, Q1 in Medicine, General & Internal
8. Wu JT, Lee CK, Cowling BJ, Yuen KY. Logistical feasibility and potential benefits of a population-wide passive-immunotherapy program during an influenza pandemic. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(7):3269-3274.
   Impact factor: 9.412; No. of citations: 27;
   Ranking: 8/71; Q1 in Multidisciplinary Sciences
9. Wu JT, Leung GM, Lipsitch M, Cooper BS, Riley S. Hedging against antiviral resistance during the next influenza pandemic using small stockpiles of an alternative chemotherapy. PLoS medicine 2009, 6(5):e1000085.
   Impact factor: 10.5; No. of citations: 69;
   Ranking: 8/165, Q1 in Medicine, General & Internal
10. Wu JT, Riley S, Fraser C, Leung GM: Reducing the impact of the next influenza pandemic using household-based public health interventions. PLoS medicine 2006, 3(9):e361.
    Impact factor: 10.5; No. of citations: 171;
    Ranking: 8/165, Q1 in Medicine, General & Internal